Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells

Prostate

Volumn 48, Issue 4, 2001, Pages 225-230

  Burchardt, Martin ^a,b   Burchardt, Tatjana ^a,b   Shabsigh, Ahmad ^a   Ghafar, Mohamed ^a   Chen, Min Wei ^a   Anastasiadis, Aristotelis ^a   de la Taille, Alexandre ^a   Kiss, Alex ^a   Buttyan, Ralph ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antisense; Dominant negative; Hormone resistance; p53; Prostate cancer

Indexed keywords

ANDROGEN; DOXYCYCLINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE MUTATION; GENETIC CODE; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; DNA, ANTISENSE; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; POINT MUTATION; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035450742     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1101     Document Type: Article

References (24)

1. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
2. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
3. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
4. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
5. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
6. Anti-apoptosis genes and the development of hormone-resistant prostate cancer
7. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
8. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
9. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancer
10. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
11. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
12. P53 and apoptosis
13. Association of p53 mutations with metastatic prostate cancer
14. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
15. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors
16. P53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
17. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer
18. Androgen-suppressed apoptosis is modified in p53 deficient mice
19. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
20. P53 functions as a cell cycle control protein in osteosarcomas
21. Stable expression of the ecotropic retrovirus receptor in amphotropic packaging cells facilities the transfer of recombinant vectors and enhances the yield of retroviral particles
22. Antisense p53 provokes changes in HeLa cell growth and morphology
23. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense
24. Identification of a minimal transforming domain of p53. Negative dominance through abrogation of sequence specific DNA binding